Log in

VistaGen Therapeutics Stock Forecast, Price & News

-0.01 (-1.41 %)
(As of 11/23/2020 12:00 AM ET)
Today's Range
Now: $0.70
50-Day Range
MA: $0.73
52-Week Range
Now: $0.70
Volume436,116 shs
Average Volume1.09 million shs
Market Capitalization$54.60 million
P/E RatioN/A
Dividend YieldN/A
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and suicidal ideation; PH94B, a neuroactive nasal spray that is in Phase III clinical trial for social anxiety disorder (SAD), and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIb clinical trial for MDD. It has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company also has a strategic licensing and collaboration agreement with EverInsight Therapeutics Inc. for the clinical development and commercialization of PH94B for multiple anxiety-related disorders in Greater China, South Korea, and Southeast Asia. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Read More
VistaGen Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VTGN



Sales & Book Value

Annual SalesN/A
Book Value($0.12) per share


Net Income$-20,770,000.00


Market Cap$54.60 million
Next Earnings Date2/11/2021 (Estimated)
OptionableNot Optionable
-0.01 (-1.41 %)
(As of 11/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

How has VistaGen Therapeutics' stock price been impacted by COVID-19?

VistaGen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VTGN shares have increased by 40.0% and is now trading at $0.70.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of VistaGen Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for VistaGen Therapeutics

What stocks does MarketBeat like better than VistaGen Therapeutics?

Wall Street analysts have given VistaGen Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VistaGen Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for VistaGen Therapeutics

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) announced its quarterly earnings data on Thursday, November, 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.03.
View VistaGen Therapeutics' earnings history

What price target have analysts set for VTGN?

3 equities research analysts have issued twelve-month target prices for VistaGen Therapeutics' shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate VistaGen Therapeutics' stock price to reach $4.50 in the next year. This suggests a possible upside of 542.9% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics

Are investors shorting VistaGen Therapeutics?

VistaGen Therapeutics saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 3,200,000 shares, an increase of 27.5% from the September 30th total of 2,510,000 shares. Based on an average daily volume of 1,790,000 shares, the short-interest ratio is presently 1.8 days.
View VistaGen Therapeutics' Short Interest

Who are some of VistaGen Therapeutics' key competitors?

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas Corp. (LAC.TO) (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

Who are VistaGen Therapeutics' key executives?

VistaGen Therapeutics' management team includes the following people:
  • Mr. Shawn K. Singh, CEO & Director (Age 57, Pay $498k)
  • Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 70, Pay $416.85k)
  • Mr. Jerrold D. Dotson CPA, CFO, VP & Sec. (Age 67, Pay $367.5k)
  • Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 54, Pay $300k)
  • Dr. Mark A. Smith, Chief Medical Officer (Age 65, Pay $416.85k)

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include D.A. Davidson & CO. (0.18%). Company insiders that own VistaGen Therapeutics stock include H Ralph Snodgrass and Jon S Saxe.
View institutional ownership trends for VistaGen Therapeutics

Which institutional investors are selling VistaGen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including D.A. Davidson & CO..
View insider buying and selling activity for VistaGen Therapeutics

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.70.

How big of a company is VistaGen Therapeutics?

VistaGen Therapeutics has a market capitalization of $54.60 million. The company earns $-20,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. VistaGen Therapeutics employs 9 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.